Close Menu

NEW YORK – Invitae on Monday said that the US Food and Drug Administration has accepted a premarket approval application for the Stratafide next-generation sequencing companion diagnostic.

Invitae acquired the test after it bought ArcherDx last month for $1.4 billion. The regulatory submission to the FDA last week triggered a milestone payment, prompting Invitae to issue 5 million shares of its common stock to former ArcherDx securityholders.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.